How the protein Rnd3 may drive lung cancer to spread
Molecular Mechanism of Rnd3 Regulation in Lung Cancer
['FUNDING_OTHER'] · UNIV OF ARKANSAS FOR MED SCIS · NIH-11250159
This work looks at how changes in the protein Rnd3 relate to lung adenocarcinoma cells becoming more likely to move and spread, which matters for people with lung cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF ARKANSAS FOR MED SCIS (nih funded) |
| Locations | 1 site (LITTLE ROCK, UNITED STATES) |
| Trial ID | NIH-11250159 on ClinicalTrials.gov |
What this research studies
From a patient's point of view, researchers are comparing tumor samples and lab-grown lung cancer cells to see how much Rnd3 is present and how that affects cancer cell movement. They use lung adenocarcinoma cell lines (like A549) and examine patient data showing differences in survival tied to Rnd3 levels. In the lab they reduce Rnd3 and watch that cells become less able to migrate and invade, two key steps in metastasis. The team is also tracing the unusual regulatory pathway that controls Rnd3, including gene-level control and chemical modifications to the protein.
Who could benefit from this research
Good fit: People with lung adenocarcinoma (a common type of lung cancer), especially those seen at or near the University of Arkansas for Medical Sciences, would be most relevant to this work.
Not a fit: People without lung adenocarcinoma (for example those with other cancer types or no cancer) are unlikely to gain direct benefit from this molecular research.
Why it matters
Potential benefit: If successful, this could point to new ways to stop or slow lung cancer metastasis and improve survival for people with lung adenocarcinoma.
How similar studies have performed: Laboratory studies have already linked Rnd3 levels to cancer cell movement, but translating those findings into patient treatments is largely untested and this project explores a new regulatory pathway.
Where this research is happening
LITTLE ROCK, UNITED STATES
- UNIV OF ARKANSAS FOR MED SCIS — LITTLE ROCK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RYAN, KATIE ROSE — UNIV OF ARKANSAS FOR MED SCIS
- Study coordinator: RYAN, KATIE ROSE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Cell Growth, Cancer Etiology, Cancer Patient, Cancer Research Programs